Contribute Try STAT+ Today

More than two dozen of the largest pharmaceutical companies are urging President Biden to reject a proposal before the World Trade Organization to temporarily waive patent rights in order to widen access to Covid-19 medical products to mostly low-income countries.

In a March 5 letter, the drug makers argue that, contrary to assertions, intellectual property is not a barrier to ensuring that vaccines and therapies become available on a global basis. Along with their trade groups, the companies also maintained that eliminating intellectual property protection to allow other manufacturers to make certain products would not speed production or access.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • What is wrong with let US, EU, UK, Canada, Switzer Kaz, Norwary, and Brazil achieve herd immunity within their own borders first then worry about and tckle the rest of the world?

Comments are closed.